• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Type I Collagen (COL1A2) Antibody – Mouse Monoclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS670188

MBS670188 is an antibody targeting COL1A2. Also known as Mouse Anti-Human Type I Collagen-BIOT. Reactive in Human. Host: Mouse. More details

$465 / 0.1 mg +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Type I Collagen (COL1A2), Monoclonal Antibody
Full Product Name
Mouse Anti-Human Type I Collagen-BIOT
Product Gene Name
Product Synonym Names
Mouse Anti-Human Type I Collagen
Clonality
Monoclonal
Isotype
IgG2b
Clone Number
4F6
Host
Mouse
Species Reactivity
Human
Form/Format
Biotin (BIOT) Conjugate
Specificity
Reacts with Human Type I Collagen. Cross reactivity with other species has not been established.
Preparation and Storage
The biotin (BIOT) conjugate is supplied as 0.1 mg in 0.2 mL PBS/NaN3. Store at 2-8 degree C.
Molecular Weight
129,314 Da
Chromosome Location
Chromosome: 7; NC_000007.13 (94023873..94060544). Location: 7q22.1
OMIM
120160
3D Structure
ModBase 3D Structure for P08123
Characterization
To insure lot-to-lot consistency, each batch of product is tested to conform to characteristics of a standard reference reagent using ELISA and/or immunohistochemistry.
Warning
Reagents contain sodium azide which is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Applications Tested/Suitable for anti-COL1A2 antibody
Immunohistochemistry (Frozen sections), ELISA
Application Notes for anti-COL1A2 antibody
ELISA: 1:5,000-1:20,000

Other Notes

Small volumes of anti-COL1A2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for COL1A2. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
type I collagen
NCBI Official Synonym Full Names
collagen, type I, alpha 2
NCBI Official Symbol
COL1A2
NCBI Official Synonym Symbols
OI4
UniProt Protein Name
Collagen alpha-2(I) chain
UniProt Synonym Protein Names
Alpha-2 type I collagen
Protein Family
UniProt Gene Name
COL1A2
UniProt Entry Name
CO1A2_HUMAN
NCBI Protein Information
collagen alpha-2(I) chain; collagen alpha-2(I) chain; type I procollagen; alpha 2(I)-collagen; alpha-2 type I collagen; collagen I, alpha-2 polypeptide; collagen of skin, tendon and bone, alpha-2 chain

NCBI Summary for COL1A2

This gene encodes the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for the alpha1 chain of type I collagen (COL1A1) reflecting the different role of alpha2 chains in matrix integrity. Three transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]
Show more

UniProt Comments for COL1A2

Function: Type I collagen is a member of group I collagen (fibrillar forming collagen).

Subunit structure: Trimers of one alpha 2(I) and two alpha 1(I) chains.

Subcellular location: Secreted › extracellular space › extracellular matrix

By similarity.

Tissue specificity: Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.

Domain: The C-terminal propeptide, also known as COLFI domain, have crucial roles in tissue growth and repair by controlling both the intracellular assembly of procollagen molecules and the extracellular assembly of collagen fibrils. It binds a calcium ion which is essential for its function

By similarity.

Post-translational modification: Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains.

Involvement in disease: Ehlers-Danlos syndrome 7B (EDS7B) [MIM:130060]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. Marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.8 Ref.9 Ref.28Osteogenesis imperfecta 1 (OI1) [MIM:166200]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI1 is a non-deforming form with normal height or mild short stature, and no dentinogenesis imperfecta.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.33 Ref.38 Ref.54 Ref.62 Ref.63Osteogenesis imperfecta 2 (OI2) [MIM:166210]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI2 is characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.18 Ref.29 Ref.30 Ref.31 Ref.34 Ref.36 Ref.37 Ref.42 Ref.44 Ref.46 Ref.48 Ref.49 Ref.56 Ref.61 Ref.63 Ref.65Ehlers-Danlos syndrome, autosomal recessive, cardiac valvular form (EDSCV) [MIM:225320]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. In addition to joint laxity, skin hyperextensibility and friability, and abnormal scar formation, patients have mitral valve prolapse and insufficiency, mitral regurgitation, and aortic insufficiency.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.60Osteogenesis imperfecta 3 (OI3) [MIM:259420]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI3 is characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera and dentinogenesis imperfecta.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.19 Ref.33 Ref.38 Ref.40 Ref.45 Ref.47 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.57 Ref.61 Ref.63Osteogenesis imperfecta 4 (OI4) [MIM:166220]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI4 is characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.12 Ref.22 Ref.32 Ref.35 Ref.41 Ref.43 Ref.44 Ref.53 Ref.61 Ref.63A chromosomal aberration involving COL1A2 may be a cause of lipoblastomas, which are benign tumors resulting from transformation of adipocytes, usually diagnosed in children. Translocation t(7;8)(p22;q13) with PLAG1.

Sequence similarities: Belongs to the fibrillar collagen family.Contains 1 fibrillar collagen NC1 domain.
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000